Announced
Completed
CICC Capital led a $100m Series C round in METiS Pharmaceuticals.
Synopsis
CICC Capital, a Chinese partially state-owned multinational investment management and financial services company, led a $100m Series C round in METiS Pharmaceuticals, a biotechnology company that aims to address unmet clinical needs. The firm will use the proceeds to advance its AI-driven drug delivery and discovery platform.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.